Crystal Structures of Inhibitor-Bound Main Protease from Delta- and Gamma-Coronaviruses

Sarah N Zvornicanin1, Ala M Shaqra1, Qiuyu J Huang1

  • 1Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.

Viruses
|March 30, 2023
PubMed

Insights

This study reveals the crystal structures of key proteases from delta and gamma coronaviruses, offering insights into inhibitor binding. These findings support the development of broad-spectrum antiviral drugs against diverse coronavirus threats.

Area of Science:

  • Virology
  • Structural Biology
  • Drug Discovery

Background:

  • The COVID-19 pandemic highlighted the zoonotic threat of coronaviruses (CoVs).
  • Research has primarily focused on alpha- and beta-CoVs due to human infections.
  • Delta and gamma-CoVs also pose zoonotic risks, necessitating further investigation.

Purpose of the Study:

  • To determine the inhibitor-bound crystal structures of the main protease (Mpro) from delta-CoV (porcine HKU15) and gamma-CoV (beluga whale SW1).
  • To analyze structural changes upon inhibitor binding.
  • To provide a basis for designing pan-coronavirus inhibitors.

Main Methods:

  • X-ray crystallography was used to determine the 3D structures of Mpro from HKU15 and SW1.
  • Cocrystallization with covalent inhibitors PF-00835231 (lufotrelvir) and GC376 was performed.
  • Comparison with the apo structure of SW1 Mpro elucidated binding mechanisms.

Main Results:

  • Inhibitor-bound crystal structures of HKU15 Mpro and SW1 Mpro were successfully determined.
  • Specific binding modes and interactions of PF-00835231 and GC376 within the Mpro active sites were revealed.
  • Structural rearrangements upon inhibitor binding were identified.

Conclusions:

  • The determined structures provide crucial insights into the inhibition of delta- and gamma-CoV Mpro.
  • These findings can guide the structure-based design of novel covalent inhibitors.
  • The study supports the development of pan-coronavirus inhibitors targeting diverse CoV genera.